Current research provides limited understanding about the clonal advantage of identified mutations in aCML, and further investigation is required to elucidate the clonal mechanisms of ASXL1, SETBP1, NRAS, and CSF3R gene mutations in relation to aCML progression and transformation. This evidence concerns the gene ASXL1 and atypical chronic myeloid leukemia, BCR-ABL1 negative.